Hybridoma technology is a popular method for antibody discovery, but the conventional approach of using a single inbred mouse strain for immunization fails to generate the diversity and antibody titers needed to maximize the discovery of high-quality leads. This white paper introduces an alternative immunization approach — the PentaMice platform, a collection of five wildtype mouse strains bred in-house for increased MHC class II diversity — and highlights how Curia is leveraging it for COVID-19 antibody discovery.
Download our white paper for insights on:
- The PentaMice platform
- Discovering SARS-CoV-2 variant-specific antibodies
- Discovering diverse, high-quality antibodies against SARS-Cov-2
More from Curia
When a drug substance requires a parenteral formulation to administer it, there are key factors to consider when choosing the ideal CDMO partner.